web analytics
10.1 C
Munich
Friday, October 7, 2022

Sunshine Biopharma, Inc. (OTCMKTS:SBFM) Goes Parabolic

Sunshine Biopharma, Inc. (OTCMKTS:SBFM) is one exciting penny stock that has transformed in recent weeks into a serious volume leader and one of the top most traded stocks on the entire bb’s. SBFM is making a highly explosive move up showing us just how parabolic these Cancer biotechs can be.

SBFM initially started moving in late December after the Company announced it has acquired all of the remaining rights, title and interest in and to all worldwide patents for the Company’s Adva-27a anticancer compound. The Patent Purchase Agreement provides Sunshine with direct ownership of all issued and pending Adva-27a related patents, which include all rights to this intellectual property worldwide. Prior, Sunshine had ownership of only the U.S. patent.

Sunshine Biopharma, Inc. (OTCMKTS:SBFM) lead anticancer compound is Adva-27a, a Topoisomerase II inhibitor, small molecule that has recently been shown to be effective at killing Pancreatic Cancer cells, Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).

Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning Phase I clinical trials of Adva-27a for Pancreatic Cancer and in parallel Multidrug Resistant Breast Cancer to be conducted at McGill University’s Jewish General Hospital in Montreal (Canada).

SBFM previously announced preclinical results showing that Adva-27a has excellent pharmacokinetics profile in rats and remarkable cytotoxic activity against a variety of multidrug resistant cancer cells including breast cancer cells and pancreatic cancer cells. Adva-27a appears to be unique in its ability to destroy multidrug resistant cancer cells. The GMP manufacturing of two kilograms of Adva-27a for clinical trials is currently underway at LONZA LTD in Switzerland. Sunshine Biopharma is planning to conduct the clinical trials of Adva-27a at McGill University’s Jewish General Hospital in Montreal, Canada. All aspects of the clinical trials in Canada will be performed in accordance with FDA approved protocols for direct filing of the results in the U.S.

CEO Dr. Steve N. Slilaty stated at the time”Allowance of the Adva-27a patent application in India represents an achievement of a major milestone in our efforts to protect the proprietary nature of this unique anticancer compound. In addition to a market comprised of a population of over 1.2 billion people, India is a major participant in the manufacturing and exportation of pharmaceutical products and raw materials around the world.”

To Find out the inside Scoop on SBFM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

SBFM traded for well over $1 in 2011 and was over $0.25 for most of 2012 as many investors put significant money into this stock because they believed in Dr. Steve N. Slilaty and his vision for Adva-27a. This vision never came to fruition however and SBFM collapsed as insiders cashed in their chips and let the stock drift into oblivion decimating the original shareholder’s investment in the Company.

The result is a large group of investors who were wiped out by SBFM and are understandably very angry with Dr. Steve N. Slilaty who was recently seen driving about town in his new black BMW M6 convertible. As SBFM hit its lowest point just over a penny Bombaykid stepped in to save the day creating a comical situation at the time.

We started reporting on SBFM after Bombaykid hit ihub earlir this year the last time it moved with ”that is not true, i work for lonza in india and sunshine pharma just bought a 10,000square feet facility, i will be working for it sunshine plant in india me very happy. Veri good news come out next week say doct karithe, veri powerful in india, doct karithe veri veri smart. Very very cheap, me buy cheap low, keep high india smart buiness peoples.”

Adva-27a is a Topoisomerase II inhibitor, small molecule that has recently been shown to be effective at killing Pancreatic Cancer cells, Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells

We have a Monster Pick Coming. Subscribe Right Now!

Currently exploding into pennyland SBFM has minimal assets or revenues and rising short term debt which resulted in significant dilution in the past. But SBFM is an exciting story here; the Company just acquired all of the remaining rights, title and interest in and to all worldwide patents for the Company’s Adva-27a anticancer compound, a promising anti cancer drug and the Company is now looking for financing to initiate clinical trials. The stock has also become a volume leader and has fast attracted a new shareholder base who is bidding it up from current levels. We will be updating on SBFM when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with SBFM.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in SBFM either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.